This from The Philadelphia Inquirer July 22, 2008; SECTION: BUSINESS; P-com Biz; Pg. C01; By Stacey Burling; Inquirer Staff Writer (Boldings mine)
These results from yet another four-year statins-vs.-aortic-stenosis study shows that statins again have no effect on the growth of aortic valve calcification, and do not extend the time before surgeries, nor reduce other AS-related cardiac mortality events.
But they sure sold a bundle of statins by making doctors think it might in the meantime. It's surprising that the myth had lingered after the last big study (Lipitor) showed absolutely no beneficial effects on aortic valve calcification as well.
Let's hope it's finally been put to rest now. False hopes fed from others' greed are a sad waste of time and resources that could have been trying to help the actual problem.
Best wishes,
Vytorin Misses Primary End Point in SEAS Study from Heartwire — a professional news service of WebMD
July 22, 2008 — Merck and Schering-Plough presented interim results of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study today, a randomized, multicenter, placebo-controlled study evaluating the effects of combination ezetimibe/simvastatin (Vytorin) on clinical outcomes in roughly 1800 patients with aortic stenosis, and the results showed that the controversial cholesterol-lowering medication was no better than placebo in reducing the primary composite end point of aortic-valve and cardiovascular events.
The combination was significantly more effective than placebo in reducing the risk of ischemic events, a secondary composite end point of nonfatal MI, coronary artery bypass graft (CABG) surgery, PCI, hospitalization for unstable angina, nonhemorrhagic stroke, and cardiovascular death. Vytorin failed to meet a secondary goal of improving aortic-valve disease events, which included valve-replacement surgery, hospitalization because of heart failure, and cardiovascular mortality.
"The SEAS study has given a clear-cut answer to the question of whether intensive lipid lowering will influence the course of aortic-stenosis disease. I think we can conclude that it does not," announced Dr Terje Pedersen (Ulleval University Hospital, Oslo, Norway), chair of the steering committee, during a conference call today with the media.
These results from yet another four-year statins-vs.-aortic-stenosis study shows that statins again have no effect on the growth of aortic valve calcification, and do not extend the time before surgeries, nor reduce other AS-related cardiac mortality events.
But they sure sold a bundle of statins by making doctors think it might in the meantime. It's surprising that the myth had lingered after the last big study (Lipitor) showed absolutely no beneficial effects on aortic valve calcification as well.
Let's hope it's finally been put to rest now. False hopes fed from others' greed are a sad waste of time and resources that could have been trying to help the actual problem.
Best wishes,
Last edited: